PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
This study is currently recruiting participants.
Verified March 2013 by Hoosier Oncology Group
Sponsor:
Hoosier Oncology Group
Collaborator:
Clovis Oncology, Inc.
Information provided by (Responsible Party):
Hoosier Oncology Group
ClinicalTrials.gov Identifier:
NCT01074970
First received: February 23, 2010
Last updated: March 6, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |